Department of Ophthalmology, University of Freiburg, Freiburg, Germany.
Ophthalmology. 2012 Sep;119(9):1924-9. doi: 10.1016/j.ophtha.2012.03.037. Epub 2012 Jun 1.
Malignant tumors metabolize glucose to lactate even in the presence of oxygen via the pentose-phosphate pathway. The metabolic switch from oxidative glycolysis to nonoxidative fermentation in tumors has been associated with overexpression of the transketolase-like-1-gene (TKTL1), which encodes an essential and rate-limiting enzyme in the nonoxidative part of the pentose-phosphate pathway. This study investigates the role of TKTL1 in ocular adnexal tumors and analyzes how its expression correlates with the clinical outcomes against the background of tumor thickness and mitotic rate.
Comparative case studies.
We included 89 subjects with malignant tumors of the ocular adnexa (44 squamous cell carcinomas, 26 lymphomas, 19 malignant melanomas) who had been treated at the University Eye Hospital Freiburg from 1994 to 2008. Sixteen subjects with conjunctival nevi, 19 with conjunctival papilloma, and 2 with conjunctival-reactive lymphoid hyperplasia were included as controls.
TKTL1 expression was assessed by reverse transcriptase-polymerase chain reaction and immunohistochemistry and semiquantitatively analyzed using an established immunoreactive score (IRS). The tumor recurrence rate, metastasis occurrence, and survival time of each patient were assessed retrospectively and correlated with the TKTL IRS using Kaplan-Meier and Cox regression analyses.
TKTL1 expression, mitotic rate within the tumor mass, and tumor thickness and its association with clinical outcome.
We identified increased TKTL1 protein levels in malignant conjunctival tumors compared with control samples and detected an average IRS of 1.78 (standard deviation [SD], ± 0.46) for melanomas, 1.3 for lymphomas (SD, ± 0.79), and 1.22 for squamous cell carcinomas (SD, ± 0. 97) compared with 0.86 for conjunctival nevi (SD, ± 0.57) and 0.5 for conjunctival papilloma (SD, ± 0.83). Multifactorial survival analysis showed that TKTL1 overexpression correlated with the patient outcomes in malignant tumors (P = 0.045). In the squamous cell carcinomas, tumor thickness and mitotic rate correlated more strongly with prognosis compared with TKTL1 overexpression (P = 0.0061, P = 0.015, and P = 0.061, respectively).
TKTL1 is dysregulated in malignant tumors of the ocular adnexa, and enhanced expression seems to predict clinical outcome, especially the tumor recurrence rate.
即使在有氧气的情况下,恶性肿瘤也通过磷酸戊糖途径将葡萄糖代谢为乳酸。肿瘤中从氧化糖酵解到非氧化发酵的代谢转换与转酮醇酶样 1 基因(TKTL1)的过度表达有关,该基因编码磷酸戊糖途径非氧化部分的关键限速酶。本研究调查了 TKTL1 在眼附属器肿瘤中的作用,并分析了其表达如何在肿瘤厚度和有丝分裂率的背景下与临床结果相关。
病例对照研究。
我们纳入了 1994 年至 2008 年期间在弗莱堡大学眼科医院治疗的 89 名眼附属器恶性肿瘤患者(44 例鳞状细胞癌、26 例淋巴瘤、19 例恶性黑色素瘤)。纳入了 16 例结膜痣、19 例结膜乳头瘤和 2 例结膜反应性淋巴组织增生作为对照。
通过逆转录-聚合酶链反应和免疫组织化学评估 TKTL1 表达,并使用既定的免疫反应评分(IRS)进行半定量分析。回顾性评估每位患者的肿瘤复发率、转移发生和生存时间,并使用 Kaplan-Meier 和 Cox 回归分析将其与 TKTL IRS 相关联。
TKTL1 表达、肿瘤内有丝分裂率以及肿瘤厚度及其与临床结果的关系。
与对照样本相比,我们在恶性结膜肿瘤中发现了增加的 TKTL1 蛋白水平,并检测到黑色素瘤的平均 IRS 为 1.78(标准差[SD],±0.46),淋巴瘤为 1.3(SD,±0.79),鳞状细胞癌为 1.22(SD,±0.97),而结膜痣为 0.86(SD,±0.57),结膜乳头瘤为 0.5(SD,±0.83)。多因素生存分析表明,TKTL1 过表达与恶性肿瘤患者的预后相关(P=0.045)。在鳞状细胞癌中,与 TKTL1 过表达相比,肿瘤厚度和有丝分裂率与预后的相关性更强(P=0.0061、P=0.015 和 P=0.061)。
TKTL1 在眼附属器的恶性肿瘤中失调,增强的表达似乎可以预测临床结果,特别是肿瘤复发率。